Palonosetron-Induced Ventricular Tachycardia in a Patient Receiving Cancer Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) is one of the major and most distressing adverse effects of cancer chemotherapy. It is treated with various antiemetic regimens, of which one class of drugs is 5-hydroxytryptamine type 3 receptor antagonists (5-HT(3) RA). Palonosetron, a potent antieme...

Descripción completa

Detalles Bibliográficos
Autores principales: M, Prasad, V K, Shashidar, Chakraborty, Ananya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602430/
https://www.ncbi.nlm.nih.gov/pubmed/28944119
http://dx.doi.org/10.7759/cureus.1480
Descripción
Sumario:Chemotherapy-induced nausea and vomiting (CINV) is one of the major and most distressing adverse effects of cancer chemotherapy. It is treated with various antiemetic regimens, of which one class of drugs is 5-hydroxytryptamine type 3 receptor antagonists (5-HT(3) RA). Palonosetron, a potent antiemetic, is a second generation 5-HT(3) RA. All 5-HT(3) antagonists, except palonosetron, have been reported to cause corrected QT interval (QTc) prolongation and certain arrhythmias. Here, we report a case of palonosetron-induced ventricular tachycardia in a 45-year-old patient receiving cancer chemotherapy.

Ejemplares similares